Hypothalamic fatty acid metabolism is involved in CNS controls of feeding and energy balance. MalonylCoA, an intermediate of fatty acid biosynthesis, is emerging as a significant player in these processes.
Introduction
Obesity is a major health problem and a major cause of insulin-resistance and diabetes. An imbalance between energy intake and energy expenditure can lead to overweight and contribute to the development of obesity and the metabolic syndrome. The hypothalamus plays a critical role in the CNS control of feeding and energy balance (21, 28) . A large body of evidence now shows that fatty acid metabolism participates in this action of the hypothalamus (1, 3, 5-7, 9, 11, 12, 15, 17, 18, 20, 23, 24) . In this regard, malonyl-CoA, an intermediate in fatty acid biosynthesis, is emerging as a significant player in the hypothalamic control of feeding and body energy balance (5-7, 9, 11, 12, 15, 18) , Recent data have linked malonyl-CoA signaling action to the hypothalamic intracellular pathways of leptin in the central regulation of energy balance (6, 9) . In the hypothalamus, leptin treatment increases malonyl-CoA level via inhibiting AMP-activated protein kinase (AMPK) and activating acetyl-CoA carboxylase (ACC) (2, 6) .
Notably, the increase of hypothalamic malonyl-CoA induced by leptin takes place specifically in the arcuate nucleus (Arc) (6), a critical site in mediating leptin's central actions on feeding and energy balance (28) . Despite these findings, the intracellular mechanisms by which malonyl-CoA impacts feeding remain unclear. It is known that malonyl-CoA inhibits the acyltransferase activity of carnitine palmitoyltransferase-1 (CPT-1) that converts long-chain fatty acyl-CoA (LCFA-CoA) to long chain acylcarnitine (9, 23) . CPT-1 has liver-and muscle-isoforms, with the hypothalamus mainly expressing the liver-isoform (CPT-1a) (23) . Pharmacological studies have demonstrated that ICV administration of compound ST-1326, a specific CPT-1a inhibitor, inhibits Arc CPT-1a activity, increases cellular LCFACoA's levels, and reduces food intake (23) . Accumulation of hypothalamic LCFA-CoA's has been suggested to have anorectic effects as ICV oleic acid (which can form LCFA-CoA's in cells) was shown to reduce food intake (24) . Given that malonyl-CoA is a physiological inhibitor of CPT-1, inhibition of Arc CPT-1a and the ensuing increase of LCFA-CoA's have been proposed to mediate malonyl-CoA's anorectic signaling actions. However, a growing body of evidence now strongly challenges this hypothesis (16) . For example, we previously demonstrated that exogenous leptin upregulates malonylCoA level without affecting the level of LCFA-CoA's in the Arc (6) . The result thus casts doubt on the role of CPT-1a as a mediator of malonyl-CoA's action in leptin feeding pathways. To clarify the role of in the Arc, we used a recombinant adenovirus expressing a mutant CPT-1a that is insensitive to malonylCoA inhibition (10) . Using this mutant, we examined the feeding responses of the animals with a disruption of malonyl-CoA-mediated inhibition on CPT-1a acyltransferase activity.
Methods

Animal preparations for feeding experiments:
Animal experiments were performed in accordance with the guidelines of the Canadian Council for Animal Care, and were approved by the University of Alberta Animal Policy and Welfare Committee. Male Sprague-Dawley rats (225-300 g) were purchased from Charles River Laboratories. The rats were housed in a controlled (12h light/12h dark) environment, and were allowed ad. lib. access to standard laboratory chow and water unless otherwise noted. Before the feeding experiments were started, the rats were handled daily and subjected to mock injections to minimize the stress from the experimental manipulation. In the leptin study, leptin or vehicle was administered at 1h before the dark onset. Food intakes at 3h and 23h (overnight) after the dark onset were monitored. Overnight body weight changes (24h after the injection) were also monitored. In the cerulenin study, at 5h before the dark onset, food was removed. Then, cerulenin or vehicle was administered and food was not provided until the dark onset. Food intakes were monitored at 3h and 19h (overnight) after dark onset. Overnight body weight changes (24h after the injection) were also monitored.
Brain sample preparations:
At the designated time points, rats were euthanized by decapitation. Brains were rapidly dissected (within 1 min) and coronal brain sections were prepared using a cryostat or a brain matrix (Roboz Surgical Instrument, Maryland). Individual hypothalamic nuclei including arcuate nucleus (Arc), ventromedial nucleus (VMN), lateral hypothalamic area (LHA) and paraventricular nucleus (PVN) were dissected according to the established protocol (6) . The accuracy of the dissection was verified by comparing the characteristic neuropeptide mRNA levels as detailed previously (6).
Recombinant adenoviruses:
The adenoviruses were delivered into the Arc (1×10 7 p.f.u. / μl; 0.4μl per side) by bilateral stereotaxic injection (6) . The coordinates were: anterior-posterior: -2.8 mm; dorsalventral: -9.5 mm; and medial-lateral: ±0.4 mm. The accuracy of the injections was confirmed by histological analysis as described previously (6) . The adenovirus encoding MCD contains the full length human MCD (hMCD) coding sequence (27) . The adenovirus encoding the wild type CPT-1a contains the nucleotide sequence (58-2700) including the entire coding region of rat CPT1a and the same sequence was used to generate the mutant CPT-1a with the 593-methionine residual mutated to serine residual (22) . The feeding experiments with leptin and cerulenin were conducted in the second week following the initial delivery of the adenoviruses. Significantly high levels of protein expressions or enzyme activities were reliably detected after one week and these high levels last until at least fourteen days (two weeks)
following the delivery of the viruses.
Cannulation surgery and intracerebroventricular injection: Cannulas were implanted into either the lateral or 3rd ventricle based on the established protocol (6) . The accuracy of placement was confirmed by angiotensin-2 drinking test or histological analysis as previously described (6) . After surgery, daily food intake and body weight were monitored. After body weights returned to the levels before surgery and the rats were fully habituated to the experimental manipulations, bolus injections of the chemicals (leptin and cerulenin) were administered ICV. Louis, MO) and 125μg in 25% DMSO/75% PBS (vehicle) was used in ICV injection as previously described (1).
Quantifications of malonyl-CoA, long-chain fatty acyl-CoA's and long-chain acylcarnitines: The
CoA recycling assay was performed to measure the malonyl-CoA level and high performance liquid chromatography (HPLC) was used to measure the levels of long-chain acyl-CoA's (consisting of palmitoyl-CoA, oleoyl-CoA and stearoyl-CoA) as detailed elsewhere (6) . To measure the levels of the long-chain acylcarnitines, brain tissues were extracted with acetonitrile and 2-propanol (6). The extracts were dried under streams of nitrogen and were reconstituted in 300 μl acetonitrile and n-butanol (1:1).
The samples were then filtered and loaded into HPLC coupled with mass spectrometer (13) . The levels of long-chain acylcarnitines (consisting of palmitoylcarnitine, oleoylcarnitine and stearoylcarnitine) were quantitated as detailed before (13) .
Malonyl-CoA decarboxylase (MCD) activity assay: Adenovirus encoding human MCD or GFP (null) was stereotaxically delivered into the Arc. Individual hypothalamic nuclei (Arc, VMN, LHA and PVN) were dissected from coronal brain sections. The MCD activity assay was performed based on established protocol (6, 27) .
Carnitine palmitoyltransferase-1 (CPT-1) activity assay: The brain was removed from the skull within 40 seconds and was immediately sectioned using the brain matrix. The mediobasal hypothalamic area (MBH), LHA and PVN were quickly dissected on ice and the tissues were immediately homogenized in the cold lysis buffer (0.25M sucrose, 5mM Tris-HCl and 1mM EGTA, pH 7.4). The crude homogenate was centrifuged at 800g for 10 minutes at 4°C. The resulting pellet was washed by resuspension in 2 volumes of the lysis buffer and was then centrifuged at 800g. This step was repeated twice to maximize the yield of the mitochondrial fraction. The combined supernatant was centrifuged at 6000g for 15 minutes at 4°C.
The resulting pellet (crude mitochondrial fraction) was gently resuspended in the lysis buffer and was used in the activity assay using a radiometric method (20) .
Antibodies and Western blotting:
The CPT-1a antibody (Ab) was generated as described elsewhere (29) . Actin (Santa Cruz Biotechnology, Santa Cruz, CA) was used as the loading control in the Western blots. The procedures of protein electrophoresis, transfer and Ab detection were performed based on standard Western protocol (Invitrogen, California). Densitometry was performed using Scion Image software (Scion, Frederick, MD).
Statistical analysis:
Data are reported as means with SE. Data consisting of two groups were analyzed by Student t-test. Data consisting of three groups were analyzed by One-way ANOVA. These One-way ANOVAs, when they yielded significant overall effects, were further analyzed by Newman-Keuls Multiple
Comparison Test for group comparisons. Data consisting of four or six groups were analyzed by Two-way ANOVA. These Two-way ANOVAs, when they yielded significant overall effects, were further analyzed by
Bonferroni posttests for group comparisons. For all tests, P<0.05 indicated significance.
Results
The M593S CPT-1a mutant is insensitive to malonyl-CoA inhibition. In this study, we used a M593S
CPT-1a mutant to address the role of CPT-1a in malonyl-CoA-mediated anorectic actions. The M593S mutation results in an impaired interaction between malonyl-CoA and the malonyl-CoA binding site in CPT-1a (22) . We first verified malonyl-CoA insensitivity of this mutant using yeast cells that do not possess endogenous CPT-1 acyltransferase activity (22) . We transfected yeast cells with the vector that expresses this mutant (CPT-1a mt) or the wild type CPT-1a (CPT-1a wt), and then measured CPT-1 acyltransferase activity using the extracts from these cells. We found that malonyl-CoA inhibitory effect on the mutant was nearly abolished (Fig. 1A) . Next, we evaluated CPT-1 acyltransferase activities in the hypothalamus. The adenovirus encoding the mutant CPT-1a (CPT-1a mt), the wild type CPT-1a (CPT-1a wt), or the null virus was delivered bilaterally into the Arc. Two weeks following delivering the viruses, rats
were euthanized and CPT-1a protein levels were quantified in individual hypothalamic nuclei (Arc, VMN, LHA and PVN). Compared to the rats injected with the null adenovirus, CPT-1a (wt or mt) adenoviral infections induced increases in CPT-1a protein levels in the Arc while the CPT-1a protein levels were not altered in the VMN, LHA or PVN (Fig. 1B) . Concomitant with the increased protein levels, CPT-1 acyltransferase activities were also increased selectively in the mediobasal hypothalamic area (MBH) encompassing the Arc (Fig. 1C) . Together, these data demonstrate Arc-specific overexpressions of CPT1a as well as activations of CPT-1 following the stereotaxic Arc delivery of the viruses. We then evaluated the response of CPT-1a to exogenous malonyl-CoA. We prepared crude mitochondrial extract from the mediobasal hypothalamic (MBH) region of the animals with Arc overexpressing the wild type CPT-1a or the mutant CPT-1a. Exogenous malonyl-CoA (50 µM) (20) was then added to the extracts and CPT-1 activity assay was conducted. As expected, we observed that the mutant CPT-1a was resistant to the inhibitory effect of malonyl-CoA (Fig. 1D) .
Increase in Arc malonyl-CoA is required for leptin's anorectic actions. Before addressing the role of CPT-1a in leptin's malonyl-CoA signaling pathway, we confirmed the importance of malonyl-CoA in the central control of feeding and in leptin's anorectic actions. The adenovirus encoding malonyl-CoA decarboxylase (Ade-MCD) (27) , which lowers malonyl-CoA level (9) , was administered into the Arc of rats. Consistent with the previous finding (9), Arc delivery of the Ade-MCD increased daily food intakes and body weight gains, compared to the rats treated with the null virus ( Fig. 2A) . Delivery of the Ade-MCD induced an increase in MCD activity in the Arc (Fig. 2B ), while the MCD activity was not altered in the VMN (Fig. 2B ) or in the LHA and PVN (LHA: MCD, 87 ± 4.7 % vs. null, 100 ± 13 %; PVN: MCD, 105 ± 1 % vs. null, 100 ± 10 %). In addition, following the delivery of the Ade-MCD, the malonyl-CoA level in the Arc was reduced (Fig. 2C) . We then administered (ICV) leptin to the rats with Arc-specific activation of MCD. As we demonstrated in the previous study (6) , leptin treatment increased malonyl-CoA level in the Arc (leptin: 220%, PBS: 100%; P<0.05). We further showed that the MCD overexpression attenuated the level of the increase in malonyl-CoA and antagonized the anorectic actions by leptin treatment (Fig. 2D ).
These results confirm that the increase in Arc malonyl-CoA level is a significant contributor to leptin's anorectic effects.
Blocking malonyl-CoA inhibition of CPT-1 acyltransferase activity does not affect leptin's anorectic actions. We injected the adenovirus encoding wild type CPT-1a (Ade-CPT-1a wt), the mutant CPT-1a (Ade-CPT-1a mt) or the null (Ade-null) into the Arc of rats. Three to four days following the virus infections, daily food intakes and body weights returned to the pre-injection levels. At least through the eighth day following the initial injection of the viruses, no significant body weight or feeding differences were found among these rats (data not shown). We then assessed the role of malonyl-CoA inhibition of CPT-1 in leptin's anorectic actions. During the second week following the initial delivery of the viruses (around the eleventh day), leptin was injected to the rats. We found that Arc overexpression of CPT-1a mt (malonyl-CoA insensitive) did not affect leptin-induced feeding inhibition or weight loss (Fig. 3A) . During this period (the second week following the injection of the viruses), the adenoviral infections did not affect the daily (24h) food intakes as compared to the basal pre-injection levels, and as in the first week described above, no significant differences of 24h food intakes were found among all treated groups (basal level: 100 ± 3.2 %, Ade-null: 103 ± 2.0 %, Ade-CPT-1a wt: 97 ± 2.1 %, Ade-CPT-1a mt: 95 ± 5.8 %). Concomitant with producing similar anorectic effects, leptin induced similar increases in Arc malonylCoA levels in all treated groups (Fig. 3B) . Since malonyl-CoA inhibition of CPT-1 acyltransferase activity is reversible (22) , the CPT-1 activity assay using tissue extract is not informative in evaluating the in vivo effect of malonyl-CoA on CPT-1 activity. CPT-1 acyltransferase activity converts long-chain fatty acylCoA's (LCFA-CoA's) to long-chain acylcarnitines (LC-AC's) (13) . We therefore assessed CPT-1a activity by measuring the levels of LC-AC's. As expected, activation of Arc CPT-1a increased LC-AC's levels in the Arc (Fig. 3C) . Leptin reduced LC-AC's levels in the Arc that ectopically expresses the wild type CPT1a (Fig. 3C) , indicating an inhibition of CPT-1 activity by leptin in these animals. In contrast, leptin did not affect LC-AC's levels in the Arc overexpressing the mutant CPT-1a (Fig. 3C) , suggesting that leptininduced accumulation of malonyl-CoA does not inhibit the CPT-1 activities in these animals. In parallel with the changes in the levels of LC-AC's, levels of total LCFA-CoA's (substrates for CPT-1a) were reduced by CPT-1a activation (Fig. 3D) . Leptin induced the increase in LCFA-CoA's levels in the Arc ectopically expressing CPT-1a wt, while it did not affect LCFA-CoA's levels in the Arc overexpressing the CPT-1a mt (Fig. 3D ). It should be noted that these biochemical assays were performed at the time when the feeding experiment with leptin was conducted (i.e. in the second week following viral injections). We also demonstrated (Fig. 1 ) that the effect of overexpressing the mutant CPT-1a on antaganizing malonylCoA-mediated inhibition remained significant at a later time point (i.e. two weeks following the viral injections). Thus, we demonstrated that during the period when the leptin-induced inhibition of CPT-1a
were blocked, the leptin-induced feeding inhibition was not affected. Taken together, these data demonstrate that blocking malonyl-CoA inhibition of CPT-1a and the resulting increase in LCFA-CoA's level does not affect leptin's anorectic actions.
Blocking malonyl-CoA inhibition of CPT-1 acyltransferase activity does not affect the anorectic action of central cerulenin. To assess the role of CPT-1a in the specific context of malonyl-CoA signaling actions, we examined the feeding response to central cerulenin that is an inhibitor of fatty acid synthase (FAS). FAS uses malonyl-CoA as a substrate and blocking FAS activity increases malonyl-CoA level (15) . We first show that overexpressing MCD attenuated the level of cerulenin-induced increase in Arc malonyl-CoA, and blocked the feeding inhibition induced by cerulenin treatment (Fig. 4A ). These data demonstrate that an increase in Arc malonyl-CoA level is required for cerulenin's anorectic effects. As expected, Arc overexpression of CPT-1a mt did not affect the anorectic effects by cerulenin, and cerulenin treatment increased Arc malonyl-CoA to a similar level in all treated groups (Fig. 4B) . It should be noted that the inhibition of FAS reduces the synthesis of long-chain fatty acids/acyl-CoA's (14) , which would contribute to lowering the LC-AC's levels via mass action. As a result, we did not monitor the CPT-1 activity following cerulenin treatment. However, we found a similar level of increase (1.5-2 fold) in Arc malonyl-CoA by cerulenin compared to that seen following leptin treatment (compare Fig. 4B with Fig.   3B ). We thus assume that cerulenin treatment produced the same effect on CPT-1a activity as leptin treatment did. Together, our data indicate that malonyl-CoA inhibition of Arc CPT-1a is not required for the anorectic effects of either leptin or cerulenin. refeeding conditions. Unexpectedly, we found that Arc LCFA-CoA's levels were increased by fasting even though the malonyl-CoA level decreased (Fig. 5A ), and these changes were reversed upon re-feeding (Fig. 5A) . Thus, in the Arc, the changes in LCFA-CoA's levels appear to dissociate from those in malonylCoA level under different feeding states. It is known that CPT-1-mediated fatty acid β-oxidation activity in the brain is trivial as compared to the periphery (16) . In determining the size of brain LCFA-CoA's pool, other actions/pathways such as exchange with the circulation, the action of acyl-CoA synthetase (ACS) and brain acyl-CoA hydrolase (BACH) play more prominent roles (Fig. 5B and ref. (16) . Here, we showed that fasting elevated the fatty acid levels in the circulation while re-feeding brought down the elevated levels (Fig. 5C) . Furthermore, the BACH activity was lowered by fasting and elevated to pre-fasting level following re-feeding (Fig. 5D) . Although the physiological relevance of these changes is unclear, these metabolic events provide an interpretation for the observed dissociation of LCFA-CoA's from malonyl-CoA.
Changes in long-
Discussion
CPT-1a, a key enzyme in regulating mitochondrial fatty acid β-oxidation, has been proposed to be a candidate for mediating hypothalamic malonyl-CoA's anorectic actions. In the CNS, as fatty acid β-oxidation activity is trivial, malonyl-CoA-mediated regulation of CPT-1 acyltransferase activity is not as significant in the brain as it is in the periphery (16) . Indeed, in our current and previous studies (6) CPT-1a is ectopically overexpressed, leptin treatment does inhibit CPT-1a activity and reduce LCFACoA's levels. However, the blockades of these changes fail to affect leptin's anorectic actions. Therefore, in the Arc, malonyl-CoA inhibition of CPT-1a seems unlikely to play a key role in mediating leptin's feeding actions. Our data also show that leptin's effect on body weight is independent of malonyl-CoAmediated CPT-1a inhibition. Together with the results of food intake, we speculate that leptin's action on body energy expenditure would also be independent of malonyl-CoA's inhibitory effect on CPT-1a.
However, a definitive conclusion requires direct measurement of energy expenditure in the experimental paradigm.
There have been increasing concerns (16) with the hypothesis that inhibiting Arc CPT-1a with the ensuing increases of LCFA-CoA's can produce anorectic effects (23, 24) . Our results provide further evidence to support the notion that these biochemical events are not implicated in leptin's anorectic actions. In addition, particularly under acute experimental conditions (24), intracellular LCFA-CoA's levels may not go up following the treatment with long-chain fatty acids (16, 24) . Moreover, a growing body of evidence now shows that accumulation of hypothalamic LCFA-CoA's is indeed associated with increase in food intake, and increases in adiposity and body weight (3, 4, 25) . Notably, ghrelin, an orexigenic factor that potently stimulates feeding, increases hypothalamic LCFA-CoA's levels while inhibits hypothalamic ACC, which reduces malonyl-CoA level (3). The observed increases in LCFA-CoA's levels suggest that the action of LCFA-CoA's, at least in ghrelin's hypothalamic pathways, can dissociate from that of malonylCoA. In line with this prediction, we demonstrate a dissociation of the levels of LCFA-CoA's from that of malonyl-CoA under fasting and re-feeding conditions. It is also worth pointing out that Arc overexpression of acyl-CoA synthetase (ACS) raising LCFA-CoA's levels does not induce the expected anorexigenic actions (personal communication with Dr. Jason Dyck, University of Alberta). Together, these data strongly challenge the proposed anorectic role of Arc LCFA-CoA's, and they also argue against the view that LCFA-CoA's can act as effectors of Arc malonyl-CoA-mediated anorectic actions.
Further challenge to a role of CPT-1a and LCFA-CoA's as mediators of malonyl-CoA feeding action comes from the study using compound C89b, a CPT-1 activator (1). It was expected that C89b treatment, by activating CPT-1a and thus reducing LCFA-CoA's levels, would stimulate food intake. Surprisingly, the study demonstrated that C89b induced the same feeding response, i.e. an inhibition, as the increase in Arc malonyl-CoA level (1). These C89b data also directly contradict the previous finding that CPT-1a inhibition (with ST1326) reduces feeding. Because opposing actions on the same targets produce similar feeding effects, these data further suggest that CPT-1a and LCFA-CoA's are not implicated in the hypothalamic control of feeding. In support of this prediction, our results are also unfavorable for a significant role of Arc CPT-1a per se in the CNS control of feeding and body weight. In our studies, we were unable to detect significant changes of either food intake or body weight gain following Arc-specific activation of CPT-1a. Furthermore, we demonstrated that CPT-1a activity (by measuring the levels of long-chain acylcarnitines) in the Arc was not significantly altered under either fasting or re-feeding condition (ad. lib. fed: 100 ± 17 %, fasted: 104 ± 14 %, re-fed: 112 ± 10 %). Taking these findings together,
Arc CPT-1a is unlikely to play a direct and key role in the central controls of feeding and energy balance.
The recent discovery of the brain-specific CPT-1 isoform, CPT-1c (26), may provide some insights into differential roles of CPT-1 isoforms in the central control of feeding and body energy balance. CPT-1c is structurally similar to CPT-1a and CPT-1b, but does not have an appreciable CPT acyltransferase activity (26, 30) . Notably, CPT-1c has been implicated in the hypothalamic control of energy balance (30) . Given 
